CAR T-Cell Therapy for Refractory Lupus Nephritis
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new CAR T-cell therapy (C-CAR168) for people with lupus nephritis that has not responded to standard treatments. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old and weigh at least 40 kg (88 lbs).
- You have a diagnosis of lupus nephritis (kidney inflammation from lupus) that has been confirmed by a kidney biopsy and has not improved with standard treatments.
- You have active lupus as shown by positive blood tests for ANA, anti-dsDNA, or anti-Smith antibodies.
- You are able to take corticosteroids and follow a tapering schedule.
- You are not pregnant or breastfeeding and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests a new type of cell treatment (BCMA-CD19 cCAR T cells) for people with lupus that has not responded well to standard therapies. It may help reduce lupus disease activity.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.